Navigation Links
Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
Date:8/19/2008

ard-looking statements include statements about the Karolinska Institute's and the SMI's plans for a prime-boost HIV vaccine clinical trial, the potential effect of the company's Vaxfectin(R) adjuvant and Biojector(R) 2000 needle-free injection system on vaccine performance, and the design and potential benefits of HIV DNA vaccines generally. Risks and uncertainties include whether Vical, the Karolinska Institute the SMI or others will continue development of the HIV vaccine; whether the SMI will sponsor and the Karolinska Institute will complete preclinical testing and conduct a Phase 1 trial using a Vaxfectin(R)-formulated DNA prime-MVA boost vaccination regimen; whether such trial, if conducted, will use the Biojector(R) 2000 needle-free injection system to deliver the DNA priming vaccine; whether Vaxfectin(R) will optimize the DNA vaccine priming of immune responses against the specific HIV vaccine targets and increase the performance of, or eliminate the need for, the MVA vaccine boost; whether Vaxfectin(R)-formulated DNA priming vaccines will increase the breadth and magnitude of immune responses to the prime-boost regimen; whether the prime- boost vaccine regimen will be effective in protecting humans against HIV infection or disease; whether the HIV vaccine will achieve the safety and immunogenicity endpoints in the Phase 1 trial; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward- looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website:

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
3. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
8. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Study ... Finds -, PRINCETON, ... of,vesicoureteral reflux (VUR) in children, reduced the incidence of recurrent,urinary tract infections ... in the July issue of the Journal of,Laparoendoscopic & Advanced Surgical Techniques. ...
... Online on Aug. 5 in Nature Journal, CLEVELAND, ... region within high density lipoprotein (HDL), the major,carrier of ... inhibiting the body,s ability to fight cholesterol buildup. ... M.D., Ph.D., Head of,the Section of Preventive Cardiology and ...
Cached Medicine Technology:DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 2DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 3DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 4Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 2Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 3
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that it will release its financial results for,the quarter ... after,the close of the U.S. financial markets. CryoCor ... at 5:00 p.m. ET /,2:00 p.m. PT on November ...
... With Business Objectives, Watson ... Survey Finds, WASHINGTON, Nov. 7 With continuing ... offer financial,incentives to reward workers who adopt healthy lifestyles, ... global consulting firm, and the,National Business Group on Health, ...
... 7 A cholesterol-lowering drug appears to disrupt sleep ... Heart Associations Scientific Sessions 2007. , The findings are ... and may have adverse health consequences, such as promoting ... lead author of the study and an associate professor ...
... Nov. 7 Exposing estrogen-sensitive breast cancer cells to ... sewer and industrial waste causes the cells to multiply, ... at the annual meeting of the American Public Health ... will be presented at a special session on Contaminants ...
... Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. 7 ... Philip Morris and R.J. Reynolds tobacco companies have,again ... by defeating a,ballot initiative to increase Oregon,s cigarette ... companies will profit by selling more cigarettes,while Oregonians ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... Operating Officer, will present at the JMP Securities,Healthcare ... 2007 at 2:30 p.m.,Eastern Time. To access ... visit the Investor Relations section of Genomic Health,s,website ...
Cached Medicine News:Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2Health News:Extracts of catfish caught in polluted waters cause breast cancer cells to multiply 2Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Genomic Health to Present at JMP Securities Healthcare Focus Conference 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
Medicine Products: